|Day Low/High||141.28 / 144.19|
|52 Wk Low/High||90.56 / 158.75|
This is a market that wants to focus on earnings, central banks, and other positive issues.
Market players celebrated news from JPMorgan Chase, Goldman Sachs and Citibank -- and it spilled over to the broader market.
Many stocks have been in a bear market and certain sectors -- like biotechnology, recent IPOs and oil -- have been under extreme pressure.
Let's consider the case of what would be the best odds on favorites to start a new position in the Dow Jones average.
The networking giant was reportedly willing to pay much more than $7 billion for infrastructure and app monitoring software firm Datadog, which delivered a strong IPO on Thursday.
Outlining Okta's earnings prospects on Wednesday is a tale of tempting TAM and troublesome valuation.
* Non-stop trading is a mugs' game * So, don't catch the "Stock Trading Jones" Speaking of my trading inactivity today, let's get back to too much trading. Here is another repost from seven years ago on this subject: This morning I want to explain ...
As NetApp tumbled and sparked a broader selloff in enterprise hardware stocks, AWS and other cloud giants are still reporting strong growth.
The catalyst for equities is now out of the bag, it is just a matter of finding companies with that catalyst before everyone catches on.
The fact that the stock's running could be because CEO Bob Swann called the bottom in data center spend.
Kimberly-Clark's performance is nothing to sneeze at, and neither is Coca-Cola's, as higher sales, higher prices and big demand from emerging markets appear to give us a return to the good old days of great senior growth stocks.
These technology picks remain big favorites for the second half of 2019.
We have some minor strength to start the day but earnings reports this week will be critical.
MSFT's results are justifying its massive market cap.
What the Fed needs to do in July is to cut the FFR by 25 basis points and put the balance sheet management (QT) program to bed two months early.
I see there is some debate about IBM in the Diary comments below, and here are my two cents... My biggest gripe with IBM is its inability to harness all of its R&D spending and convert it into revenue. I'm not sure if the management thinks they are...
It's a stock picker's market as action in individual stocks is better than on the indexes.
I don't expect to see the bears and shorts press too hard right now but there isn't going to be much upside momentum.
There are still stock-picking opportunities, but tighten stops and don't let losses build.
Now that the numbers are actually hitting, it's difficult to place faith in possible lower interest rates to offset for poor growth.
The market remains muted on the news, with bad headlines leading to dip-buying and good news failing to produce protracted momentum.
Preventing the U.S. dollar from appreciating too aggressively while repairing credit conditions are 'job freaking one'.
Don't be rigid in your thesis, keep an eye on market action and respond as appropriate.
It is still a surprisingly sedate market, despite indexes sitting close to all-time highs, earnings season, possible interest-rate cuts and endless speculation about China trade.
Traders and investors were disappointed recently when the IT company did not raise guidance and that weakness does not look like it has run its course.
IBM is likely to take one of two paths.
The deal makes sense for growth - and for Allergan shareholders - but now the price and uncertainty make this stock hard to swallow.
Do we finally have too many new stocks, and are we running out of ammunition to buy them without wholesale liquidation of other stocks?
Oracle tells investors it can regain the crown it once held among enterprises and end-users, but some aren't so sure.